BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

ZLB Behring L.L.C. 

A CSL Company
1020 First Avenue
King of Prussia  Pennsylvania  19406  U.S.A.
Phone: 610-878-4000 Fax: 610-878-4009


SEARCH JOBS


Industry
Biotechnology






 Company News
ZLB Behring Foundation Calls For Grant Applications 11/16/2006 11:58:35 AM    More...
ZLB Behring Names Robert D. Lefebvre, Ronan W. Gannon, Garrett E. Bergman, M.D., To Top U.S. Management Posts 9/18/2006 10:34:59 AM    More...
ZLB Behring Release: VIRTUE, Largest Clinical Trial Of Subcutaneous Immunoglobulin Therapy, Opens To Primary Immunodeficiency Patients Across The U.S. 9/12/2006 12:07:23 PM    More...
ZLB Behring Foundation Calls For Grant Applications 6/22/2006 2:01:13 PM    More...
ZLB Behring Foundation Awards Grants To Benefit Bleeding Disorders Community 6/5/2006 2:42:05 PM    More...
ZLB Behring Release: New International Study Group Seeks To Set Standards For Prevention, Treatment Of Bleeding In Patients With von Willebrand Disease (VWD) 5/23/2006 11:17:36 AM    More...
ZLB Behring Release: First International Census On Von Willebrand Disease (VWD): 77 Percent Of Patients With Severe Type 3 VWD Experience Significant Bleeding-Related Events 5/22/2006 11:26:24 AM    More...
State-Of-The-Art ZLB Behring Plant Licensed By The FDA 4/18/2006 2:33:41 PM    More...
ZLB Behring Release: Study Finds Treatment With C1-Inhibitor Concentrate Relieves Abdominal Pain In Hereditary Angioedema Patients 3/6/2006 11:33:48 AM    More...
ZLB Behring Release: Study Shows Individual Replacement Therapy With C1-Inhibitor Concentrate Reduces Life-Threatening Hereditary Angioedema Attacks Compared With Current Treatment Of Choice 3/6/2006 11:13:50 AM    More...
123

//-->